Month: February 2023
-
Bio-Electric Regeneration Company Adds $8M in Seed Funds
A start-up enterprise, spun-off from Tufts University labs, creating bio-electrical treatments for regenerating limbs and tissue, is raising $8 million in new seed funds.
-
Quantum, AI Systems Company Gains $500M in New Funds
A developer of systems with quantum computing and artificial intelligence as a service, initially for security applications, is raising $500 million in new venture funds.
-
Biotech Drug Shown to Kill Prostate Tumor Cells
Tests with lab mice show low doses of an experimental oral drug can selectively kill prostate cancer cells while not affecting surrounding healthy tissue.
-
Nasal Spray Reduces Flu Duration in Challenge Trial
An influenza vaccine given as a nasal spray is shown in a clinical trial to reduce the amount of time participants have flu infections, when exposed to the virus.
-
Infographic – The Earth’s Converging Plates
Among the forces beneath the earth’s surface are the movements of tectonic plates, large shifting and sliding slabs of rock, where at their boundaries most earthquakes and volcanoes occur.
-
Clinical Trial Underway Testing Influenza Vaccine Patch
A clinical trial has begun testing a commercially-available flu vaccine administered with a painless patch device against conventional syringe injection delivery.
-
Green Energy Chemical Company Starts-Up, Raises $15M
A new enterprise, spun-off from labs at Northwestern University, says it’s designing electrochemical processes and systems for nanoscale materials to help meet the climate crisis.
-
Data Support Placebo Group Alternatives in Rare Disease Trials
Findings from a review of medical data and records indicate matched genetic control groups may not be needed in clinical trials testing treatments for Duchenne muscular dystrophy.
-
AI-Aided Mobile App Shown to Screen for Melanoma
The developer of an app using algorithms to analyze images of skin lesions says clinical trial findings show the system detects melanoma more reliably than some physicians.
-
Allergy Antibody Biotech Gains $40M in New Funds
A biotechnology enterprise creating engineered antibodies to treat severe food allergies is raising $40 million in its second venture financing round.